{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["115(9)"],"submitter":["Chiorean EG"],"journal":["British journal of cancer"],"pagination":["e13"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5117797"],"repository":["biostudies-literature"],"pubmed_title":["Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer."],"pmcid":["PMC5117797"],"pubmed_authors":["Liu H","Harris M","Whorf R","Manax V","Tabernero J","El-Maraghi R","Wee Ma W","Reni M","Romano A","Lu B","Goldstein D","Chiorean EG","Von Hoff DD","Shiansong Li J"],"additional_accession":[]},"is_claimable":false,"name":"Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.","description":null,"dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Oct","modification":"2025-04-21T19:17:03.182Z","creation":"2025-04-05T17:33:16.284Z"},"accession":"S-EPMC5117797","cross_references":{"pubmed":["27657342"],"doi":["10.1038/bjc.2016.306"]}}